Welcome to BrainStorm Cell Therapeutics
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
HACKENSACK, New Jersey and PETACH TIKVAH, Israel – April 14, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015. Read More...
Click here for our Company Presentation at the Stem Cell on the Mesa meeting in San Diego, October 2013.
Click here for a summary of the data presented at the American Academy of Neurology meeting, March 2013.